PharmaLex taps DocShifter for PDF generation

Published: 11-Jan-2022
Regulatory Digital

DocShifter is a document conversion and validation solution for pharmaceutical, biotech and medical device companies

PharmaLex, a service provider for the pharmaceutical, biotech and medical device industries, has chosen DocShifter for the generation of PDF documents for its client base. PharmaLex's services include document pre-publishing and regulatory submission publishing, therefore managing large numbers of documents in different formats and differing levels of quality is a high priority.

DocShifter is a document conversion and validation solution for pharmaceutical, biotech and medical device companies. The software is designed to automate, accelerate and simplify the way companies create submission-ready PDFs from original source documents; no matter which system these documents reside in. According to the company, the software can automatically validate the PDF output against health authority requirements, fix errors and return a report to ensure compliance.

"Our clients need their eCTD sequences to be published quickly, accurately and efficiently. Our aim is to go above and beyond in delivering compliance solutions, by combining existing state-of-the-art software and our established know-how, and DocShifter fits perfectly into our strategy. DocShifter saves us a lot of time (on average, we estimate 5 minutes per document, multiplied by thousands of documents), reduces the risk of non-compliance, increases the quality of PDF renditions; allowing us to realise real, immediate and lasting benefits for our clients," said Jennie May, Director of Regulatory Informatics & Operations at PharmaLex.

The company says its software’s flexibility to connect with multiple systems, check and fix Word and PDF documents and simultaneously generate submission-ready PDF documents for multiple health authorities improves operational efficiency in regulatory and beyond, with one centralised platform.

"Working with PharmaLex has been a great experience. I've known them for a while, and they have always been known for delivering exceptional services. We are very happy we can contribute to PharmaLex living up to the promises they make to their customers." says Paul Ireland, VP Life Sciences at DocShifter.

  • Companies:
  • PharmaLex
See more

You may also like

Regulatory

The right validation model: practical considerations and applications

Read more
It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Trending Articles

  1. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  4. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer
  5. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

The right validation model: practical considerations and applications

It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
Regulatory

European Commission adopts proposal to delay MDR deadlines

With thousands of outstanding conformity assessments for medical device certification under the Medical Device Regulation and limited capacity to manage these within the transition period, concerns about widespread product shortages in the EU market have been growing
Regulatory

Investment, outsourcing and globalisation: key trends for 2023

The start of 2023 has been challenging for the pharmaceutical industry. Economic constraints in Europe and the United States, staffing shortages, an increasingly complex regulatory environment and heightened competition for funding is putting pressure on companies
Finance

PharmaLex expands Nordic footprint across key business units with DRA Consulting merger

Alliance strengthens long-held collaboration and builds on overall regulatory, quality and market access services while advancing digital expertise
Regulatory

PharmaLex extends reach in Asia with Ascent merger

Headquartered in Tokyo, Ascent employs staff across Asia, and provides country-specific knowledge mixed with strategic advice from a global perspective
Regulatory

Why Bayesian statistics is revolutionising pharmaceutical decision making

PharmaLex's Bruno Boulanger, Global Head of Statistics and Data Science, and Brad Carlin, Senior Adviser for Statistics and Data Science, explore the growing significance of Bayesian statistics in supporting decision-making across the development and regulatory processes and its potential to improve outcomes for the biopharmaceutical industry
Regulatory

EFSA declares titanium dioxide unsafe for food products

Thomas Eberwein, Head of Pharmaceutical Quality at Pharmalex, explains the EFSA’s recent decision to declare titanium dioxide unsafe for food products, and the implications for manufacturers
Subscribe now